J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 30.32 CNY 0.83% Market Closed
Market Cap: 24.2B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Jafron Biomedical Co Ltd
Income to Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jafron Biomedical Co Ltd
Income to Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income to Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Income to Minority Interest
ÂĄ10.4m
CAGR 3-Years
90%
CAGR 5-Years
39%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Income to Minority Interest
ÂĄ11.8m
CAGR 3-Years
21%
CAGR 5-Years
20%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Income to Minority Interest
ÂĄ3.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Income to Minority Interest
-ÂĄ60.5m
CAGR 3-Years
-165%
CAGR 5-Years
-76%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Income to Minority Interest
ÂĄ34.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Income to Minority Interest
-ÂĄ3.5m
CAGR 3-Years
53%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.5B CNY
Industry
Health Care

In the heart of China's bustling Guangdong province, Jafron Biomedical Co., Ltd. has carved a distinguished niche in the world of biomedicine since its inception. This innovative company, recognized as a leader in the hemoperfusion field, has built its reputation on a foundation of pioneering blood purification technologies. By developing and manufacturing an array of hemoperfusion devices, Jafron offers critical solutions that aid in the removal of toxins from the bloodstream, thus improving outcomes for patients suffering from various systemic toxic reactions and kidney-related disorders. Their state-of-the-art hemoperfusion cartridges, meticulously designed for efficiency, are instrumental in managing and treating conditions such as chronic kidney disease and liver dysfunction. This relentless pursuit of quality is bolstered by a dedicated research division that harmonizes clinical insights with scientific innovation, ensuring Jafron stays at the forefront of clinical demand. Jafron Biomedical thrives on a robust business model that fuses direct sales with an expansive network of partnerships. This dual approach not only amplifies their market reach but also enables the company to establish solid footholds in key domestic and international markets. By collaborating with healthcare institutions and medical device distributors, Jafron ensures its products deliver critical health solutions to a broad clientele. The revenue streams are mainly anchored in the sales of its hemoperfusion products and through strategic expansions in emerging markets. As global health standards evolve and the demand for advanced medical solutions expands, Jafron is positioned to sustain its growth momentum by continually innovating in response to the global demand for efficient blood purification therapies. Through these methods, Jafron not only augments its economic footprint but also underscores its commitment to enhancing global healthcare standards.

Intrinsic Value
48.46 CNY
Undervaluation 37%
Intrinsic Value
Price
J

See Also

What is Jafron Biomedical Co Ltd's Income to Minority Interest?
Income to Minority Interest
10.4m CNY

Based on the financial report for Sep 30, 2024, Jafron Biomedical Co Ltd's Income to Minority Interest amounts to 10.4m CNY.

What is Jafron Biomedical Co Ltd's Income to Minority Interest growth rate?
Income to Minority Interest CAGR 5Y
39%

Over the last year, the Income to Minority Interest growth was 38%. The average annual Income to Minority Interest growth rates for Jafron Biomedical Co Ltd have been 90% over the past three years , 39% over the past five years .

Back to Top